Predict your next investment

Corporate Venture
are.com/venture-investments.html

See what CB Insights has to offer

Investments

312

Portfolio Exits

64

Funds

1

About Alexandria Venture Investments

Alexandria Venture Investments, the strategic investment arm of Alexandria Center® at Kendall Square, has been supporting innovation and entrepreneurship by investing important and significant capital in the broad and diverse science and technology sectors. Alexandria is uniquely positioned to fund science and advanced technology companies based on experience and in-depth understanding of the science and technology industries, its long-term relationships with top-tier science and technology investors and research institutions, and its world-class international network.

Alexandria Venture Investments Headquarter Location

Pasadena, California,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Alexandria Venture Investments

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Alexandria Venture Investments in 1 Expert Collection, including Game Changers 2018.

G

Game Changers 2018

20 items

Research containing Alexandria Venture Investments

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Alexandria Venture Investments in 1 CB Insights research brief, most recently on Aug 5, 2021.

Latest Alexandria Venture Investments News

Pheast Therapeutics Raises $76M in Series A Funding

Apr 27, 2022

Pheast Therapeutics , a Palo Alto, CA-based company developing checkpoint therapies to fight cancer, raised $76M in Series A funding. The round was led by Catalio Capital Management and ARCH Venture Partners with participation from Alexandria Venture Investments and Risk and Reward. The company intend sto use the funds to expand its management, scientific, and administrative teams, as well as towards R&D to advance its pipeline of innate immune checkpoint inhibitors towards the clinic. Led by scientific experts Dr. Amira Barkal, MD, PhD, Dr. Irving Weissman, MD, Dr. Ravi Majeti, MD, PhD, and Dr. Roy Maute, PhD., Pheast is a pre-clinical stage immuno-oncology company focused on targeting cancer immune evasion pathways to activate the innate immune system in the fight against cancer. Its primary program targets the surface protein CD24, a “don’t eat me” signal commandeered by many cancers, including ovarian and breast cancer, in order to avoid detection and clearance by intra-tumoral macrophages. Pheast is also leveraging its proprietary discovery platform to enable the development of additional novel tumor-specific cancer immunotherapies. FinSMEs 27/04/2022

Alexandria Venture Investments Investments

312 Investments

Alexandria Venture Investments has made 312 investments. Their latest investment was in DEM BioPharma as part of their Series A on June 6, 2022.

CBI Logo

Alexandria Venture Investments Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/23/2022

Series A

DEM BioPharma

$70M

Yes

3

5/25/2022

Seed VC

Pleno

$15M

Yes

8

5/17/2022

Series B

Remix Therapeutics

$70M

No

5

5/10/2022

Series B

Subscribe to see more

$99M

Subscribe to see more

10

5/9/2022

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/23/2022

5/25/2022

5/17/2022

5/10/2022

5/9/2022

Round

Series A

Seed VC

Series B

Series B

Series B

Company

DEM BioPharma

Pleno

Remix Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$70M

$15M

$70M

$99M

$99M

New?

Yes

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

3

8

5

10

10

Alexandria Venture Investments Portfolio Exits

64 Portfolio Exits

Alexandria Venture Investments has 64 portfolio exits. Their latest portfolio exit was Tara Biosystems on April 05, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

4/5/2022

Acquired

$99M

3

2/3/2022

Reverse Merger

$99M

3

1/7/2022

IPO

$99M

Public

7

10/29/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

9/24/2021

Reverse Merger

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/5/2022

2/3/2022

1/7/2022

10/29/2021

9/24/2021

Exit

Acquired

Reverse Merger

IPO

IPO

Reverse Merger

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Sources

3

3

7

10

10

Alexandria Venture Investments Fund History

1 Fund History

Alexandria Venture Investments has 1 fund, including Alexandria Seed Fund.

Closing Date

Fund

Fund Type

Status

Amount

Sources

Alexandria Seed Fund

3

Closing Date

Fund

Alexandria Seed Fund

Fund Type

Status

Amount

Sources

3

Alexandria Venture Investments Team

1 Team Member

Alexandria Venture Investments has 1 team member, including current Senior Vice President, Jenna Foger.

Name

Work History

Title

Status

Jenna Foger

Senior Vice President

Current

Name

Jenna Foger

Work History

Title

Senior Vice President

Status

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.